VALI
Valion Bio and 3i, LP amend Series B side letter for closing option
Valion Bio and 3i, LP amended their prior Side Letter, supporting the Purchaser's right to close on up to $1,600,000 of Series B Preferred Shares and warrants.
VALI news
Latest 2 stories · newest Oct 27, 2026
VALI
Valion Bio appoints Dean Zikria interim CEO effective Sep 22, 2026
Valion Bio, Inc. signed a consulting agreement with Dean Zikria as Interim Chief Executive Officer, effective September 22, 2026. The deal includes monthly fees, RSUs, and cash bonuses tied to strategic transactions.
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.
The same VALI feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/VALI/newsSTART FREE